Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

DOI: 10.1186/s13195-019-0520-1

Keywords: Verubecestat, BACE inhibitor, Amyloid, Alzheimer’s disease, Clinical trial, Safety

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text